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We evaluated the use of the molecular bacterial load (MBL) assay, for measuring viableMycobacterium tuberculosis in sputum,
in comparison with solid agar and liquid culture. TheMBL assay provides early information on the rate of decline in bacterial
load and has technical advantages over culture in either form.
Assessment of Mycobacterium tuberculosis sputum bacterialload has routinely been performed using solid culture (1).
Automated liquid culture has been proposed as an alternative (2),
but all culture-based methods are hampered by contamination
with other microorganisms (3), protracted time to obtain results
(4), and populations of viable, nonculturable bacteria (5, 6). We
recently described the molecular bacterial load (MBL) assay,
based on 16S rRNA, observing that MBL declined biphasically in
response to treatment (7). In the present study, we directly com-
pared the MBL assay with solid and liquid culture on 148 sputum
samples (collected overnight from 1600 h until 0800 h the follow-
ing morning) from 20 patients enrolled and hospitalized at the
EBA Unit, Tanzanian National Institute for Medical Research-
Mbeya Medical Research Centre, Tanzania. Samples were col-
lected pretreatment (2 overnight samples) and longitudinally
(days 2, 4, 5, 7, 10, and 14) during standard WHO treatment for
drug-sensitive tuberculosis. The OEBA (Observation of Early
Bactericidal Activity) study was a capacity building project of
the PanACEA consortium. Before patient enrolment, the study
was approved by the site’s local ethics board (reference MRH/
T.30/44/2) and national ethics board (reference NIMR/HQ/
R.8a/Vol.IX/1169) and the sponsor (University of Munich)
ethics board. The study was conducted in compliance with the
declaration of Helsinki. All patients provided written informed
consent to study participation, including use of their samples
for evaluation of novel molecular assays. The study was regis-
tered in the Pan African Clinical Trials Registry (pactr.org)
under PACTR201209000394102.
Sputum was homogenized, and one half was decontaminated
withN-acetyl-L-cysteine-sodium hydroxide (1% final NaOH con-
centration) prior to inoculation into mycobacterial growth indi-
cator tubes (BBL MGIT; Becton, Dickinson and Company, MD,
USA), according to the manufacturer’s instructions, in order to
determine time to positivity (TTP) in the Bactec MGIT 960 (Bec-
ton, Dickinson and Company, MD, USA). The second portion
was mixed with an equal volume of Sputasol (Oxoid, Limited,
United Kingdom), and quadruplicate 100-l volumes of 10-fold
dilutions were inoculated onto 7H11 agar containing Mycobacte-
ria Selectatab Kirchner supplement (Mast Group, Limited, United
Kingdom). Nine hundred fifty microliters of sputum/Sputasol
was preserved in guanidine thiocyanate containing 1%-mercap-
toethanol, and the MBL assay was performed as detailed in the
work of Honeyborne et al. (7). MBL value was assigned based on
16S rRNA cycle threshold (CT) using the normalized 16S rRNACT
in the following equation: bacterial load (log10)  (normalized
16S CT 31.76)/3.171 (7).
Artificial sputum (see Text S1 in the supplemental material)
developed as a matrix for high assay standards was found to be a
good substitute for pooled human sputum. High standards had
mean 7.46 log10 bacilli (standard error of the mean [SEM], 0.08)
and 7.49 log10 bacilli (SEM, 0.07) (P  0.80) for pooled human
sputum and artificial sputum, respectively (see Fig. S1 in the sup-
plemental material). The low standard mean of 3.70 log10 bacilli
(SEM, 0.13) for pooled human sputum was statistically different
from that of artificial sputum (mean, 3.38 log10 bacilli; SEM, 0.13;
P  0.01) (see Fig. S1). However, the SEMs are identical for the
two matrices, and therefore, the critical factor, reproducibility of
extraction of an assigned bacterial number, was met.
Spearman rank correlations for 148 sputum samples revealed a
high degree of correlation between the assays: log10 MBL com-
pared to solid agar log10 CFU (r0.84; 95% confidence interval
[CI], 0.78, 0.88), log10 MBL compared to solid agar log10 TTP (r
0.81; 95% CI,0.86,0.74), and log10 TTP compared to solid
agar log10 CFU (r  0.78; 95% CI, 0.84, 0.71; for all, P 
0.0001) (see Fig. S2 and Text S2 in the supplemental material).
Correlation between log10 CFU and log10 TTP for our study was
comparable to that in a study of2,000 sputum samples tested in
South Africa (r  0.72) (2), although TTP was not log-trans-
formed in this study.
Direct comparison of solid culture and the MBL assay for in-
dividual patients revealed that the declines in bacterial load closely
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matched during the first 14 days of therapy (Fig. 1). rRNA is
downregulated in bacteria that are entering dormancy (8), and so
one might expect that the MBL assay is an underestimate of bac-
terial load. However, the baseline median bacterial load was 0.43
log10 (95% CI, 0.12, 0.73; P 0.008) higher when measured using
the MBL assay than when measured by the solid agar CFU method
(paired t test, P  0.008). This may be explained by the selective
antibiotics in the solid agar method killing a proportion of the
bacteria present. We observed a similar effect for six clinical iso-
lates (M. tuberculosis [n  5] and Mycobacterium bovis [n  1])
isolated from decontaminated sputum on Lowenstein-Jensen (LJ)
slopes (Southern Group Laboratories, Limited, United King-
dom). Determination of bacterial number for these was done us-
ing the Miles-Misra method (9) on 7H10 agar with 10% oleic
acid-albumin-dextrose-catalase (OADC) supplement (Becton,
Dickinson and Company, MD, USA) with and without the addi-
tion of antibiotics using bacteria subcultured from the LJ slope
into 7H9 medium containing 0.2% Tween 80 and 10% ADC sup-
plement (Becton, Dickinson and Company, MD, USA). Addition
of antibiotics (Mycobacteria Selectatabs Kirchner; Mast Group,
Limited, United Kingdom) reduced the bacterial count by 0.47
log10 (95% CI, 0.23, 0.71; paired t test, P  0.004). This may
explain the increased MBL readout observed here for patient spu-
tum in comparison to that for solid culture despite comparable
rates of decline.
A biphasic decline in bacterial load was observed for liquid and
solid culture and the MBL assay with a node at day 3 (Fig. 2). Full
details of statistical analysis are given in Text S2 in the supplemen-
tal material. The decline rate for days 0 to 3 for solid agar was
0.278 log10 day
1 (95% confidence interval, 0.345, 0.212),
and that for MBL was0.307 log10 day
1 (0.389,0.226). MBL
decline was therefore slightly quicker over the first 3 days, al-
though the confidence intervals overlap. The use of mRNA for the
isocitrate lyase gene and the use of noncoding ribosomal pro-
moter region mRNA as amplification targets for bacterial quanti-
fication have previously been found to respond comparably to
culture during days 2 to 7 of therapy but not during the first 2 days
of therapy (10). In contrast, MBL robustly matched solid and liq-
uid culture over the early phase of treatment. Extended early bac-
tericidal activities (EBAs) from days 3 to 14 were also comparable,
with 0.082 log10 (0.119, 0.045) and 0.124 log10 (0.170,
0.079) for CFU on solid medium and MBL, respectively. These
data match other EBA studies measuring treatment response with
solid culture (11–16). The close comparability between MBL and
culture contrasts with data for treatment monitoring using the
GeneXpert MTB/RIF assay (Xpert; Cepheid, CA, USA). Gene-
Xpert MTB/RIF did not respond to changes in bacterial load as
rapidly as did culture (17). Within-subject variation of Xpert was
high, at 56.7%. In contrast, MBL had a 9.6% variance between 2
baseline samples for 16 subjects (18), suggesting that MBL is more
reproducible. To corroborate this, within-patient variabilities for
solid (17.9%) and liquid (21.6%) culture in our study were com-
pared to those in the study by Kayigire et al., with 16.5% and 22%,
respectively (18). Prior to exclusion of outliers, solid culture had
invalid results in 11% of samples (18 of 169), whereas MBL had
only 1.2% of samples (2 of 169) unreadable.
FIG 1 Individual patient plots comparing bacterial load measured using solid agar and MBL during the first 14 days of treatment for 20 individuals.
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In summary, our data show that the MBL assay is at least as
good as culture for measuring EBA during standard tuberculosis
therapy to day 14, with higher precision, fewer missing data, and a
shorter time to result (24 h compared to weeks). This assay shows
promise as a replacement for culture in future EBA trials testing
new drugs.
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